Shares of AEON Biopharma Inc. (AEON) are down over 55% at $1.49 in premarket trading Friday, following disappointing phase II trial results of ABP-450 in the preventive treatment for chronic migraine.
ABP-450, the company's lead candidate, is a 900-kDa botulinum toxin type A complex.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com